Rubius, after layoffs and executive turnover, sets plan to dissolve
WEBFeb 22, 2023 · Rubius Therapeutics on Wednesday revealed plans to shut down and liquidate its assets, four years after it went public at a nearly $2 billion valuation with the goal to re-engineer blood cells to fight disease.
Rubius Therapeutics to shut down. It's a lesson for biotech - STAT
WEBFeb 22, 2023 · On Wednesday, the company — battered down to a market value of $15 million — said it was shutting down and liquidating all of its remaining assets. The official end of Rubius marks one of ...
Rubius Therapeutics Outlines Dissolution Plan, After Unsuccessful ...
WEBFeb 22, 2023 · In September, Rubius Therapeutics announced plans to restructure and align resources to advance its next-generation red blood cell-based cell conjugation platform. It discontinued Phase 1 trials...
Rubius moves to dissolve after last-ditch effort - Fierce Biotech
WEBFeb 22, 2023 · After a last-ditch effort last year to try to refocus, the Cambridge, Massachusetts-based company will now liquidate and dissolve. Rubius announced the news in a Securities and Exchange...
Rubius Therapeutics Announces Strategic Update - GlobeNewswire
WEBSep 13, 2022 · Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform. Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023 ...
Rubius, a once high-flying biotech startup, lays off much of its staff
WEBSep 13, 2022 · Rubius Therapeutics, a biotechnology company aiming to turn engineered blood cells into medicines, will lay off 75% of its staff and stop development of its two most advanced drug prospects.
Rubius Therapeutics Announces Process to Explore Strategic …
WEBNov 2, 2022 · Rubius is employing cell conjugation to generate therapeutic red blood cells with two distinct modalities – potent cell-cell interaction and tolerance induction.
Rubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It …
WEBAug 11, 2022 · Rubius Therapeutics, Inc. (RUBY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rubius Therapeutics Announces Process to Explore Strategic
WEBNov 2, 2022 · Rubius is employing cell conjugation to generate therapeutic red blood cells with two distinct modalities – potent cell-cell interaction and tolerance induction.
Rubius scraps lead candidate as it exits rare disease drugmaking
WEBMar 12, 2020 · Rubius Therapeutics will end development of its most advanced drug as the Cambridge, Massachusetts-based biotech looks to save money by moving away from rare disease research.